Lupin to expand its Vadodara facility: Report

03 Mar 2014 Evaluate

In a bid to make bulk drugs for cardiac, anti-infectives, anti-tuberculosis, neurology and other segments, Lupin is reportedly planning to expand its Vadodara facility. In this regard, the company will invest around Rs 270 crore.

The Dabhasa plant of Lupin near Vadodara is one of the leading bulk drug manufacturing sites for the company. The Dabhasa plant is one of our major active pharmaceutical ingredient manufacturing sites which also exports. It is a US Food and Drug Administration (USFDA) approved facility.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2125.80 -21.80 (-1.02%)
28-Jan-2026 15:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1608.80
Dr. Reddys Lab 1221.00
Cipla 1329.20
Zydus Lifesciences 896.55
Lupin 2125.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×